Oncology-Based In-Vivo CRO Market Growth Supported By Rising Cancer Prevalence

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Oncology Based In-Vivo CRO Market During The Forecast Period?

The oncology based in-vivo cro market size has seen rapid expansion in recent years. It is forecast to grow from $1.5 billion in 2025 to $1.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. The market’s development in the preceding period is attributable to the heightened demand for preclinical oncology studies, the increasing adoption of animal model-based research, the rising incidence of blood cancers and solid tumors, the global enlargement of contract research organizations, and stricter regulatory prerequisites for preclinical validation.

The oncology based in-vivo cro market size is projected to experience substantial expansion over the next few years, reaching $2.54 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.2%. This anticipated growth can be ascribed to a heightened focus on patient-derived xenograft models, the increasing integration of digital data management systems, the advancement in personalized oncology drug development, the rising outsourcing of in-vivo studies to specialized CROs, and the growing adoption of automated imaging and monitoring solutions. Prominent trends throughout this forecast period involve the increasing uptake of digital platforms for in-vivo study management, the expanded application of AI and machine learning in preclinical oncology research, the wider implementation of genomic profiling for patient-derived xenograft models, greater automation in in-vivo testing and data analysis, and the increasing use of IoT-enabled monitoring for laboratory equipment and study outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which Key Drivers Are Affecting The Oncology Based In-Vivo CRO Market Development?

The rising prevalence of cancer is anticipated to stimulate the expansion of the oncology-based in-vivo CRO market moving forward. Cancer describes a collection of illnesses where abnormal cells divide uncontrollably, extend beyond their normal boundaries, originate in almost any body organ or tissue, and disseminate to other parts of the body via the blood and lymph systems. The treatment and diagnosis of cancer necessitate innovative drugs and devices, which must undergo various preclinical trials, clinical trials, and regulatory procedures before their market release. An oncology in-vivo-based CRO is a firm engaged by a sponsor company to offer research services, such as carrying out all or part of the stages of a preclinical in-vivo study (involving testing with living organisms like animals, plants, or whole cells) before the drug or device is tested in humans. With the increasing incidence of cancer, the demand for novel treatments and therapies has also grown, thereby propelling the growth of the oncology-based in-vivo CRO market. For example, in April 2024, the American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases identified in the country in 2022. An estimated 620,000 cancer deaths are projected for 2024, representing a minor increase in mortality rates. This escalating prevalence of cancer is driving the oncology-based in-vitro CRO market.

Which Segment Classifications Are Used In The Oncology Based In-Vivo CRO Market Segment Analysis?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

What Trends Are Transforming The Oncology Based In-Vivo CRO Market?

Major companies in the oncology-based in vivo CRO market are concentrating on developing innovative solutions, including CAR T-cell therapies, to gain a market advantage. CAR T-cell therapy is a form of immunotherapy that utilizes specially altered T cells to fight cancer. For instance, in May 2023, Seattle, a US-based Children’s Hospital and Research Institute, launched BrainChild Bio with the goal of accelerating CAR T-cell therapies for children suffering from brain tumors. The primary pediatric brain tumors BrainChild Bio plans to target with CAR T-cell therapy are diffuse intrinsic pontine gliomas (DIPG), an incurable childhood disease that develops in the brainstem. BrainChild Bio operates as a next-generation CAR T-cell treatment platform, incorporating synthetic technologies to maximize the effectiveness of CAR T-cell therapies for CNS malignancies. After achieving pediatric registration for DIPG, BrainChild Bio intends to apply its innovative CAR T-cell therapy to treat a wider range of challenging-to-cure adult and pediatric brain tumors, such as glioblastoma and brain metastases.

Which Firms Are Contributing To The Oncology Based In-Vivo CRO Market Ecosystem?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Get The Full Oncology Based In-Vivo CRO Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Which Region Represents The Largest Share Of The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oncology Based In-Vivo CRO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Specialty Foods Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-foods-global-market-report

Community Oncology Services Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795